rHIgM22

N/A

Report date: 2024/04/10 13:52:15

Base Information

Drug NamerHIgM22

Drug Alias NameM22rHIgM22

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionMyelin proteins stimulants

TargetsMyelin proteins

Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMayo Clinic

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAcorda Therapeutics

Active IndicationsN/A

Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Other Information

ATC CodeN/A